NEW YORK CITY, NY / ACCESS Newswire / July 29, 2025 / DoubleVerify Holdings Inc. (NYSE:DV)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose to investors material information. Specifically, the Company failed to disclose that: (1) DoubleVerify’s customers were shifting their ad spending from open exchanges to closed platforms, where the Company’s technological capabilities were limited and competed directly with native tools provided by platforms like Meta Platforms and Amazon; (2) DoubleVerify’s ability to monetize on Activation Services, the Company’s high-margin advertising optimization services segment, was limited because the development of its technology for closed platforms was significantly more expensive and time-consuming than disclosed to investors; (3) DoubleVerify’s Activation Services in connection with certain closed platforms would take several years to monetize; (4) DoubleVerify’s competitors were better positioned to incorporate AI into their offerings on closed platforms, which impaired the Company’s ability to compete effectively and adversely impacted the Company’s profits; (5) DoubleVerify systematically overbilled its customers for ad impressions served to declared bots operating out of known data center server farms; (6) DoubleVerify’s risk disclosures were materially false and misleading because they characterized adverse facts that had already materialized as mere possibilities; and (7) as a result of the foregoing, the Company’s positive statements about the its business, operations, and prospects were materially false and/or misleading or lacked a reasonable basis.
If you are a DV investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
Capricor Therapeutics, Inc. (NASDAQ:CAPR)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose to investors material information. The Company provided investors with material information concerning Capricor’s lead cell therapy candidate drug deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy. The Company’s statements included, among other things, Capricor’s ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration.
Allegedly, the Company provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel.
If you are a CAPR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
Neogen Corporation (NASDAQ:NEOG)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose to investors material information. In December 2021, it was announced that Neogen would merge with the Food Safety Division of the 3M Company. The deal closed in September 2022. Upon closing, Neogen commenced what would become a lengthy and complicated integration process. On January 25, 2025, the Company revealed, among other things, that GAAP net income in the second quarter was significantly negative due to a $461 million non-cash goodwill impairment charge related to the 3M acquisition. In addition, the Company revealed that, as of November 30, 2024, the Company had material weaknesses in its internal control over financial reporting. On this news, the price of the Company’s common stock declined 5% to close at $12.36 per share.
Allegedly, the Company misrepresented the status of the 3M integration and failed to disclose the negative impact of integration issues on the financial health of Neogen.
If you are a NEOG investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
Alto Neuroscience, Inc. (NYSE:ANRO)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose to investors material information. Specifically, the Company allegedly made false and/or misleading statements and/or failed to disclose that: (1) ALTO-100 was less effective in treating MDD than the Company had led investors to believe; (2) accordingly, ALTO-100’s clinical, regulatory, and commercial prospects were overstated; (3) as a result, Alto’s business and/or financial prospects were overstated; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you are an ANRO investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
ATTORNEY ADVERTISING.© 2025 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact:
Joshua M. Lifshitz, Esq.
Lifshitz Law PLLC
Phone: 516-493-9780
Facsimile: 516-280-7376
Email: jlifshitz@lifshitzlaw.com
SOURCE: Lifshitz Law Firm
View the original press release on ACCESS Newswire
COMTEX_467655908/2457/2025-07-29T14:48:03